184 related articles for article (PubMed ID: 34750932)
41. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
[TBL] [Abstract][Full Text] [Related]
42. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
44. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
45. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
46. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
47. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya.
Ting J; Mugo N; Kwatampora J; Hill C; Chitwa M; Patel S; Gakure H; Kimani J; Schoenbach VJ; Poole C; Smith JS
Sex Transm Dis; 2013 Jul; 40(7):584-9. PubMed ID: 23965776
[TBL] [Abstract][Full Text] [Related]
48. Atypical squamous cells of undetermined significance in liquid-based cytologic specimens: results of reflex human papillomavirus testing and histologic follow-up in routine practice with comparison of interpretive and probabilistic reporting methods.
Levi AW; Kelly DP; Rosenthal DL; Ronnett BM
Cancer; 2003 Aug; 99(4):191-7. PubMed ID: 12925979
[TBL] [Abstract][Full Text] [Related]
49. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
50. High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests.
Zuo T; Levi AW; Lin Q; Abi-Raad R; Adeniran AJ; Cai G
Am J Clin Pathol; 2021 Sep; 156(4):569-576. PubMed ID: 33728437
[TBL] [Abstract][Full Text] [Related]
51. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia?
Adam E; Kaufman RH; Berkova Z; Icenogle J; Reeves WC
Am J Obstet Gynecol; 1998 Jun; 178(6):1235-44. PubMed ID: 9662307
[TBL] [Abstract][Full Text] [Related]
52. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
[TBL] [Abstract][Full Text] [Related]
53. Clinical performance of the aptima HPV assay in 4196 women with positive high-risk HPV and ASC-US cytology: A large women hospital experience.
Wang T; Pradhan D; Zhang H; Matsko J; Zhao C
Diagn Cytopathol; 2021 Jan; 49(1):5-10. PubMed ID: 32857920
[TBL] [Abstract][Full Text] [Related]
54. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
55. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
56. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions.
Leinonen MK; Schee K; Jonassen CM; Lie AK; Nystrand CF; Rangberg A; Furre IE; Johansson MJ; Tropé A; Sjøborg KD; Castle PE; Nygård M
J Clin Virol; 2018; 99-100():22-30. PubMed ID: 29289814
[TBL] [Abstract][Full Text] [Related]
57. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
[TBL] [Abstract][Full Text] [Related]
58. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
[TBL] [Abstract][Full Text] [Related]
59. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
Mayrand MH; Duarte-Franco E; Rodrigues I; Walter SD; Hanley J; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
N Engl J Med; 2007 Oct; 357(16):1579-88. PubMed ID: 17942871
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
